Stock listing

LSE:0A4C Altimmune, Inc. Share Price

UK listing (LSE) of Altimmune, Inc. · home listing NASDAQ:ALT

Follow Altimmune, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ALT

$1.33 USD -0.06 (-4.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ALT

Past year -70.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.32 – $1.46 USDNov 20, 2026
Volume
4.02M sharesNov 20, 2026
Market cap
$258.8M USDAt the close on Nov 20, 2026 · price × 194.6M shares outstanding
52-week range
$1.32 – $6.44 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$10.16M USDMedian day 3.51M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Altimmune, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ALT · Home$1.33 USD-0.06 (-4.3%)4,019,048$1.37$1.46$1.32$1.39Close on Nov 20, 2026
Frankfurt:3G0€1.202 EUR-0.072 (-5.7%)3,100€1.25€1.25€1.202€1.274Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.33-0.06-4.3%$1.37$1.46$1.324,019,048
$1.39-0.14-9.2%$1.52$1.53$1.384,687,477
$1.53-0.03-1.9%$1.55$1.56$1.4954,245,713
$1.56-0.085-5.2%$1.64$1.665$1.506,046,935
$1.645+0.035+2.2%$1.64$1.67$1.583,501,696
$1.61-0.32-16.6%$1.89$1.90$1.6012,373,048
$1.93-0.01-0.5%$1.95$1.985$1.902,921,884
$1.94-0.18-8.5%$2.12$2.13$1.903,988,810
$2.12+0.04+1.9%$2.097$2.21$2.054,360,690
$2.08+0.11+5.6%$1.97$2.095$1.952,760,352
$1.97-0.15-7.1%$2.12$2.127$1.914,191,051
$2.12+0.08+3.9%$2.10$2.15$2.0253,473,692
$2.04+0.02+1.0%$2.03$2.08$2.032,385,659
$2.02-0.02-1.0%$2.07$2.106$2.012,736,052
$2.04-0.10-4.7%$2.10$2.13$1.993,514,346
$2.14+0.04+1.9%$2.13$2.18$2.102,652,607
$2.10+0.06+2.9%$2.02$2.10$1.9954,313,240
$2.04-0.01-0.5%$2.085$2.15$2.014,942,516
$2.05-0.07-3.3%$2.14$2.14$2.023,485,419
$2.12-0.05-2.3%$2.16$2.20$2.062,599,076
$2.17-0.06-2.7%$2.20$2.24$2.153,089,620
$2.23-0.07-3.0%$2.31$2.35$2.194,486,247
$2.30+0.07+3.1%$2.22$2.32$2.202,229,237
$2.23+0.03+1.4%$2.22$2.26$2.182,600,535
$2.20-0.16-6.8%$2.365$2.369$2.174,240,400
$2.36+0.05+2.2%$2.31$2.38$2.293,344,400
$2.31-0.12-4.9%$2.40$2.41$2.295,623,700
$2.43-0.13-5.1%$2.56$2.56$2.433,713,400
$2.56-0.05-1.9%$2.59$2.625$2.562,158,700
$2.61+0.01+0.4%$2.60$2.64$2.572,677,700
$2.60-0.06-2.3%$2.66$2.66$2.554,929,500
$2.66-0.01-0.4%$2.64$2.74$2.633,168,200
$2.670.000.0%$2.70$2.70$2.647,623,300
$2.67-0.065-2.4%$2.73$2.747$2.653,839,500
$2.735-0.025-0.9%$2.80$2.81$2.714,243,900
$2.76-0.10-3.5%$2.85$2.85$2.753,589,100
$2.86-0.11-3.7%$2.99$2.99$2.864,922,500
$2.97+0.01+0.3%$2.99$3.006$2.922,561,000
$2.96-0.10-3.3%$3.04$3.07$2.953,357,500
$3.06+0.02+0.7%$3.05$3.11$3.002,858,800
$3.04-0.15-4.7%$3.18$3.20$2.983,685,800
$3.19-0.22-6.5%$3.42$3.425$3.154,531,500
$3.41+0.14+4.3%$3.33$3.41$3.254,003,300
$3.27+0.02+0.6%$3.31$3.34$3.243,516,200
$3.25+0.01+0.3%$3.23$3.26$3.1812,175,800
$3.240.000.0%$3.31$3.35$3.213,456,600
$3.24+0.01+0.3%$3.27$3.29$3.1953,328,800
$3.23-0.07-2.1%$3.30$3.31$3.212,334,500
$3.30+0.03+0.9%$3.27$3.36$3.272,460,900
$3.27-0.02-0.6%$3.33$3.41$3.262,704,700
$3.29-0.06-1.8%$3.32$3.345$3.252,563,000
$3.35-0.01-0.3%$3.35$3.425$3.2913,069,900
$3.36-0.06-1.8%$3.46$3.55$3.343,588,400
$3.42+0.19+5.9%$3.28$3.43$3.254,867,100
$3.23-0.05-1.5%$3.30$3.32$3.192,550,400
$3.28+0.19+6.1%$3.10$3.34$3.107,470,000
$3.09-0.02-0.6%$3.07$3.095$3.022,355,200
$3.110.000.0%$3.08$3.135$3.062,216,400
$3.11-0.13-4.0%$3.21$3.23$3.063,188,500
$3.24+0.09+2.9%$3.19$3.25$3.132,276,800
$3.15-0.05-1.6%$3.20$3.20$3.094,046,200
$3.20+0.09+2.9%$3.14$3.225$3.113,814,600
$3.110.000.0%$3.13$3.13$3.0252,715,900
$3.11+0.16+5.4%$2.98$3.24$2.956,148,000
$2.95-0.17-5.4%$3.07$3.08$2.924,681,400

Splits

1 split · NASDAQ:ALT · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
Ticker
LSE:0A4C
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
USD

What changed lately

Latest news

All Altimmune, Inc. news

Altimmune, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
30 in the last 12 months · 179 in all · newest Nov 19, 2026 · oldest 2019
Calls
27 calls with a replay · 27 with a transcript · latest Nov 12, 2026
Decks
31 decks · latest Nov 9, 2026

Where Altimmune, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ALT · Home listingNASDAQUnited StatesUSD
gettex:3G0gettexGermanyEUR
Lang & Schwarz:A2N5Z6Lang & SchwarzGermanyEUR
LS Exchange:A2N5Z6LS ExchangeGermanyEUR
BMV:ALT1BMVMexicoMXN
BIVA:ALT1BIVAMexicoMXN
Tradegate:3G0TradegateGermanyEUR
BOATS:ALTBOATSUnited StatesUSD
LSE:0A4C · This pageLSEUnited KingdomUSD
Dusseldorf:3G0DusseldorfGermanyEUR
Frankfurt:3G0FrankfurtGermanyEUR
Hamburg:3G0HamburgGermanyEUR
Munich:3G0MunichGermanyEUR
Stuttgart:3G0StuttgartGermanyEUR

Valuation

Price/book 0.6× against a median of 2.0×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$28.73M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.55

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Altimmune, Inc. · NASDAQ:ALTUS$258.8MUS$28.73Mn/an/an/a0.6×n/a0.1×1.55
Kyverna Therapeutics, Inc. · NASDAQ:KYTXUS$263.5MUS$117.8Mn/an/an/a2.0×n/a0.2×2.02
PepGen Inc. · NASDAQ:PEPGUS$261.8MUS$172.6Mn/an/an/a2.5×n/a0.1×1.11
Ocugen, Inc. · NASDAQ:OCGNUS$260.6MUS$178.1Mn/a37.3×n/an/an/an/a1.47
Prelude Therapeutics Incorporated · NASDAQ:PRLDUS$258.6MUS$136.2Mn/a6.3×n/a2.1×−247.1%0.1×1.48
OBI Pharma, Inc. · TPEX:4174US$258.5MUS$243.4Mn/a154×n/a5.7×n/a0.0×n/a
TransThera Sciences (Nanjing). Inc. · HKEX:2617US$257.1MUS$119.4Mn/an/an/a2.0×n/a0.0×n/a
Eikon Therapeutics, Inc. · NASDAQ:EIKNUS$256.8MUS$44.67Mn/an/an/a0.7×n/a0.7×1.91
SAB Biotherapeutics, Inc. · NASDAQ:SABSUS$255.7MUS$156.5Mn/an/an/a1.2×n/a0.0×1.19
Evommune, Inc. · NYSE:EVMNUS$255.5MUS$86.86Mn/an/an/a1.0×n/a0.0×0.96
Editas Medicine, Inc. · NASDAQ:EDITUS$253.1MUS$119.7Mn/a2.4×n/a3.0×−144.9%0.7×2.22
Median of the othersUS$257.8MUS$128.0M21.8×2.0×−196.0%0.1×1.48

Forecasts

7 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
16.67 USD · Analysts' mean
EPS, year to Dec 2026
-0.62 · 5 analysts

Team and board

Officers

OfficerRole
Jerome DursoPresident, Chief Executive Officer and Chairman Of The Board
Greg WeaverChief Financial Officer
Robin E. AbramsChief Legal Officer
Christophe Arbet-EngelsChief Medical Officer
Linda M. RichardsonChief Commercial Officer
Scot RobertsChief Scientific Officer

Board

DirectorRole
Jerome DursoPresident, Chief Executive Officer and Chairman Of The Board
Alex HowarthDirector
Catherine Angell SohnDirector
Diane K. JorkaskyDirector
John M. GillDirector
Mitchel SayareDirector
Peter GreenleafDirector
Philip HodgesDirector
Teri LawverDirector
Wayne PisanoDirector

Events

Calls

CallWhenStatus
Altimmune (NASDAQ:ALT) Q3 2026 Earnings CallThu, Nov 12, 2026 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q2 2026 Earnings CallWed, Aug 12, 2026 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q1 2026 Earnings CallWed, May 13, 2026 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q4 2025 Earnings CallThu, Mar 05, 2026 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q3 2025 Earnings CallThu, Nov 06, 2025 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q2 2025 Earnings CallTue, Aug 12, 2025 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q1 2025 Earnings CallTue, May 13, 2025 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q4 2024 Earnings CallThu, Feb 27, 2025 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q3 2024 Earnings CallTue, Nov 12, 2024 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q2 2024 Earnings CallThu, Aug 08, 2024 · 8:30 AM ETReplay
All 27 calls
CallWhenStatus
Altimmune (NASDAQ:ALT) Q1 2024 Earnings CallThu, May 09, 2024 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q4 2023 Earnings CallWed, Mar 27, 2024 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q3 2023 Earnings CallTue, Nov 07, 2023Replay
Altimmune (NASDAQ:ALT) Q2 2023 Earnings CallThu, Aug 10, 2023 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q1 2023 Earnings CallThu, May 11, 2023 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q4 2022 Earnings CallTue, Feb 28, 2023 · 11:00 AM ETReplay
Altimmune (NASDAQ:ALT) Q3 2022 Earnings CallThu, Nov 10, 2022 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q2 2022 Earnings CallThu, Aug 11, 2022 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q1 2022 Earnings CallThu, May 12, 2022 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q4 2021 Earnings CallTue, Mar 15, 2022 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q3 2021 Earnings CallWed, Nov 10, 2021 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q2 2021 Earnings CallWed, Aug 11, 2021 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q1 2021 Earnings CallMon, May 17, 2021 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q4 2020 Earnings CallThu, Feb 25, 2021 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q3 2020 Earnings CallTue, Nov 10, 2020 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q2 2020 Earnings CallWed, Aug 12, 2020 · 8:30 AM ETReplay
Altimmune (NASDAQ:ALT) Q1 2020 Earnings CallThu, May 14, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−16.6%
Q2 2026Aug 12, 2026 · Before open−2.3%
Q1 2026May 13, 2026 · Before open−1.9%
Q4 2025Mar 26, 2026−8.8%
Q3 2025Nov 6, 2025 · Before open+5.1%
Q2 2025Aug 12, 2025 · Before open+7.1%
Q1 2025May 13, 2025 · Before open−4.2%
Q4 2024Mar 25, 2025 · Before open−2.6%
Q3 2024Nov 12, 2024 · Before open+29.1%
Q2 2024Aug 8, 2024 · Before open+15.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open+7.8%
Q4 2023Mar 27, 2024 · Before open+2.8%
Q3 2023Nov 7, 2023 · Before open+1.1%
Q2 2023Aug 10, 2023 · Before open+3.0%
Q1 2023May 11, 2023 · Before open+7.0%
Q4 2022Feb 28, 2023 · Before open+6.4%
Q3 2022Nov 10, 2022 · Before open+9.2%
Q2 2022Aug 11, 2022 · After close+26.1%
Q1 2022May 12, 2022 · Before open+8.6%
Q4 2021Mar 15, 2022 · Before open−8.2%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (November 2026)Technical17 slidesNov 9, 2026
AASLD The Liver Meeting 2026Conference19 slidesNov 8, 2026
Technical Presentation (November 2026)Technical16 slidesNov 7, 2026
Q2 2026 Earnings PresentationEarnings38 slidesAug 12, 2026
Technical Presentation (July 2026)Technical19 slidesJul 28, 2026
Q4 2025 Earnings PresentationEarnings32 slidesMar 5, 2026
Technical Presentation (December 2025)Technical20 slidesDecember 2025
Technical Presentation (June 2025)Technical23 slidesJun 26, 2025
Investor Presentation (May 2025)Investor deck39 slidesMay 2025
Technical Presentation (November 2023)Technical19 slidesNov 30, 2023
All 31 decks
DeckKindSlidesDate
Technical Presentation (March 2023)Technical25 slidesMar 21, 2023
Technical Presentation (December 2022)Technical20 slidesDec 20, 2022
Technical Presentation (September 2022)Technical18 slidesSep 14, 2022
Technical Presentation (2022)Technical18 slides2022
Q1 2021 Earnings PresentationEarnings13 slidesMay 17, 2021
Investor Presentation (June 2020)Investor deck10 slidesJune 2020
BIO Investor Forum 2019Conference20 slidesOct 23, 2019
Merger or Acquisition (July 2019)Merger or acquisition17 slidesJul 9, 2019
Pharmathene — Merger or Acquisition (April 2017)Merger or acquisition24 slidesApr 27, 2017
Pharmathene — Merger or Acquisition (February 2017)Merger or acquisition23 slidesFeb 13, 2017
Pharmathene — Merger or Acquisition (February 2017)Merger or acquisition25 slidesFeb 1, 2017
Pharmathene — Bio Investor Forum San Francisco 2013Conference23 slidesOct 8, 2013
Pharmathene — Merger or Acquisition (September 2013)Merger or acquisition36 slidesSep 9, 2013
Pharmathene — Rodman & Renshaw Annual Global Investment Conference 2013Conference23 slidesSep 9, 2013
Pharmathene — Merger or Acquisition (August 2013)Merger or acquisition21 slidesAug 1, 2013
Pharmathene — Rodman & Renshaw 14th Annual Healthcare Conference 2012Conference21 slidesSep 10, 2012
Pharmathene — Investor Presentation (December 2008)Investor deck25 slidesDec 10, 2008
Pharmathene — Investor Presentation (August 2008)Investor deck28 slidesAug 29, 2008
Pharmathene — Investor Presentation (July 2008)Investor deck27 slidesJul 23, 2008
Healthcare Acquisition — SPAC Merger (January 2007)SPAC merger32 slidesJan 24, 2007
Healthcare Acquisition — SPAC Merger (January 2007)SPAC merger32 slidesJan 22, 2007

Open Decks

Financings

RaiseDate
Public offering of common stock and accompanying common stock warrants (or pre-funded warrants in lieu thereof)
Closed: US$225M raised · US$3 a share · Warrants at US$3 · Leerink Partners +2
Dealers: Leerink Partners (co-lead), Barclays (co-lead), Titan Partners (co-lead)
Buyers: Deep Track Capital (led the financing); TCGX; Viking Global Investors; RA Capital Management
Use of proceeds: Fund the upcoming Phase 3 trial in MASH, plus working capital and general corporate purposes
Apr 27, 2026
Registered direct offering of common stock (or pre-funded warrants in lieu thereof)
Closed: US$75M raised · Titan Partners, a division of American Capital Partners
Dealers: Titan Partners, a division of American Capital Partners (lead)
Buyers: new fundamental institutional investor (17,045,454 shares of common stock (or pre-funded warrants in lieu thereof))
Use of proceeds: Upcoming Phase 3 trial in MASH, working capital and general corporate purposes
Jan 29, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue41.0K20.0K426.0K-68.0K4.41M8.19M5.80M10.3M10.7M3.24M
Cost of revenue112.0K238.0K477.0K500.0K73.8M33.5M17.1M18.5M18.4M7.22M
Gross profit41.0K20.0K426.0K-68.0K4.41M-25.3M5.80M-8.13M-18.4M-1.99M
Research and development66.4M82.2M65.8M70.5M74.5M49.8M17.8M18.5M18.4M7.22M
Selling, general and administrative28.1M21.0M18.1M17.1M15.4M13.2M8.50M9.77M8.46M11.5M
Operating income-94.5M-103.2M-95.9M-87.7M-96.9M-54.8M-21.5M-42.8M-52.0M-11.1M
Depreciation and amortization112.0K238.0K477.0K-205.0K551.3K428.9K387.3K218.7K83.8K63.1K
EBITDA-94.4M-102.9M-95.5M-87.9M-96.4M-54.4M-21.1M-42.6M-52.0M-11.0M
Interest expense1.64M9.00K35.0K8.00K5.00K9.42K2.24K297.1K162.1K38.5K
Income before tax-88.8M-95.1M-88.4M-84.9M-97.1M-54.5M-20.6M-45.3M-52.1M-11.1M
Income tax-681.0K309.1K-197.0K-919.5K-5.42M-58.5K-6.15M-5.64M0
Net income-88.1M-95.1M-88.4M-84.7M-97.1M-49.0M-20.5M-39.2M-46.4M-11.1M
Earnings per share, basic-1.00-1.34-1.66-1.81-2.35-1.91-1.60-15.16-118.912.97
Earnings per share, diluted-1.00-1.34-1.66-1.81-2.35-1.91-1.60-15.16-118.912.95

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents43.8M36.9M135.1M111.1M190.3M115.9M8.96M33.7M8.77M2.88M
Short-term investments229.7M95.0M62.7M73.8M0100.0M28.3M3.53M66.8M
Receivables1.74M3.12M4.85M2.54M5.84M12.4M1.65M4.47M10.2M999.1K
Inventory34.0K-13.4B-1.96B-503.9M3.53M0
Current assets278.2M137.3M209.6M192.8M204.1M230.3M39.4M39.4M23.5M4.49M
Property, plant and equipment312.0K413.0K651.0K1.08M1.45M1.06M1.10M1.34M603.1K177.9K
Goodwill00018.8M
Total assets279.9M139.3M210.6M206.9M218.9M245.1M54.1M54.8M63.0M38.4M
Accounts payable2.72M211.0K2.07M4.80M2.03M612.3K18.2K372.9K129.1K2.01M
Current liabilities15.0M10.5M12.1M17.1M18.3M12.0M3.92M4.53M3.84M5.47M
Long-term debt34.3M4.58M1.45M1.83M1.86M1.85M4.57M526.0K
Total debt34.3M1.68M671.0K4.58M1.45M1.83M1.86M572.8K599.9K526.0K
Total liabilities55.0M15.8M16.5M21.6M19.7M19.2M8.54M6.44M14.4M6.19M
Shareholders' equity224.9M123.5M194.1M185.3M199.1M225.9M45.5M48.3M39.4M32.2M
Shares outstanding110.9M72.4M70.7M49.2M41.0M37.1M15.3M9.08M608.5K6.92M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-67.5M-79.8M-75.8M-62.6M-78.2M-34.3M-9.60M-9.39M-20.2M-6.35M
Capital spending-11.0K0-47.0K-126.0K-12.1M-204.0K-1.23K-975.4K-112.4K-125.0K
Free cash flow-67.5M-79.8M-75.9M-62.7M-90.4M-34.5M-9.60M-10.4M-20.3M-6.48M
Cash from investing-132.5M-28.4M13.7M-73.4M87.5M-72.2M-28.3M-1.00M13.7M-220.6K
Cash from financing206.8M10.0M86.1M56.8M65.1M213.5M12.5M32.5M15.8M4.98M
Dividends paid-135.5M-3.79B-22.9K00
Share buybacks291.0K300.0K215.0K-516.0K224.5M135.5M3.79B-2.39M13.0M3.80M
Change in cash6.83M-98.2M24.0M-79.2M74.4M107.0M-25.4M22.0M9.43M138.4M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
8-K · Current reportOct 29, 2026FinancingSEC
8-K · Current reportOct 27, 2026Management or board changeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 2, 2026Insider tradeSEC
8-K · Current reportSep 29, 2026Management or board changeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
8-K · Current reportJul 28, 2026Current reportSEC
8-K · Current reportJun 16, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMay 13, 2026Offer documentSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 1, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 1, 2026Big-stake noticeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 1, 2026Big-stake noticeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 30, 2026Big-stake noticeSEC
8-K · Current reportApr 24, 2026Material contractSEC
424B5 · ProspectusApr 23, 2026Offer documentSEC
S-3MEFApr 22, 2026Other filingsSEC
424B5 · ProspectusApr 22, 2026Offer documentSEC
8-K · Current reportApr 16, 2026Meeting outcomeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersMar 17, 2026Annual reportSEC
DEF 14A · Proxy statementMar 17, 2026Meeting noticeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementMar 6, 2026Meeting noticeSEC
10-K · Annual reportMar 6, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
S-8 · Registration statement for employee plansFeb 6, 2026Offer documentSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
8-K · Current reportFeb 3, 2026Current reportSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
8-K · Current reportJan 28, 2026Material contractSEC
424B5 · ProspectusJan 28, 2026Offer documentSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
8-K · Current reportDec 19, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveDec 8, 2025Other filingsSEC
CORRESP · Letter to the SECDec 3, 2025Other filingsSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
8-K · Current reportDec 1, 2025Management or board changeSEC
S-3/A · Registration statement, amendedNov 13, 2025Offer documentSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
S-3 · Registration statementNov 6, 2025Offer documentSEC
8-K · Current reportNov 6, 2025Material contractSEC
424B5 · ProspectusNov 6, 2025Offer documentSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 3, 2025Insider tradeSEC
8-K · Current reportOct 3, 2025Management or board changeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
8-K · Current reportSep 25, 2025Meeting outcomeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 17, 2025Insider tradeSEC
UPLOAD · Letter from the SECAug 19, 2025Other filingsSEC
ARS · Annual report to shareholdersAug 15, 2025Annual reportSEC
DEF 14A · Proxy statementAug 15, 2025Meeting noticeSEC
CORRESP · Letter to the SECAug 12, 2025Other filingsSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
UPLOAD · Letter from the SECAug 8, 2025Other filingsSEC
4 · Change in ownershipAug 4, 2025Insider tradeSEC
4 · Change in ownershipAug 4, 2025Insider tradeSEC
4 · Change in ownershipAug 4, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
8-K · Current reportJun 26, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 14, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveMar 14, 2025Other filingsSEC
8-K · Current reportMar 13, 2025Current reportSEC
4 · Change in ownershipMar 11, 2025Insider tradeSEC
CORRESP · Letter to the SECMar 11, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 5, 2025Other filingsSEC
S-3 · Registration statementFeb 27, 2025Offer documentSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 25, 2025Insider tradeSEC
8-K · Current reportFeb 25, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
8-K · Current reportDec 11, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 12, 2024Insider tradeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
8-K · Current reportNov 12, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedOct 17, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 16, 2024Big-stake noticeSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
8-K · Current reportSep 26, 2024Meeting outcomeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
ARS · Annual report to shareholdersAug 15, 2024Annual reportSEC
DEF 14A · Proxy statementAug 15, 2024Meeting noticeSEC
8-K · Current reportAug 15, 2024Management or board changeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJul 10, 2024Big-stake noticeSEC
3 · Initial statement of ownershipJul 1, 2024Insider tradeSEC
8-K · Current reportJun 26, 2024Management or board changeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedApr 10, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 27, 2024Offer documentSEC
10-K · Annual reportMar 27, 2024Annual reportSEC
8-K · Current reportMar 27, 2024ResultsSEC
SC 13G · Big-stake noticeMar 5, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Altimmune, Inc.’s releases · as of Nov 6, 2026

Common shares
194,589,451
Fully diluted
194,589,451

Fully diluted

LineSharesAs of
Common shares194,589,451Nov 6, 2026

Warrants and options

Lot
Warrants · US$3.00 · expiry not stated

Share count over time

CountShares
Nov 6, 2026194,589,451

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock21M10.8%US$59.9MSep 30, 2026
Deep Track Capital, LP19.3M9.9%US$55.1MSep 30, 2026
Vanguard17.1M8.8%US$49MSep 30, 2026
State Street8.36M4.3%US$23.9MSep 30, 2026
Viking Global Investors LP6.7M3.4%US$19.2MSep 30, 2026
Ra Capital Management, L.P.6.5M3.3%US$18.6MSep 30, 2026
Marshall Wace, LLP5.43M2.8%US$15.5MSep 30, 2026
Geode Capital4.88M2.5%US$14MSep 30, 2026
Two Sigma4.27M2.2%US$12.2MSep 30, 2026
Trails Edge Capital Partners, LP4.23M2.2%US$12.1MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Millennium3.84M2.0%US$11MSep 30, 2026
Woodline Partners LP3.4M1.7%US$9.72MSep 30, 2026
Goldman Sachs2.48M1.3%US$7.09MSep 30, 2026
Nuveen2.15M1.1%US$6.14MSep 30, 2026
Weiss Asset Management LP2.03M1.0%US$5.8MSep 30, 2026
Great Point Partners LLC1.74M0.89%US$4.98MSep 30, 2026
Nantahala Capital Management, LLC1.72M0.88%US$4.92MSep 30, 2026
Fidelity1.61M0.83%US$4.61MSep 30, 2026
Susquehanna1.54M0.79%US$4.41MSep 30, 2026
Point72 Asset Management, L.P.1.46M0.75%US$4.17MSep 30, 2026
Northern Trust1.46M0.75%US$4.17MSep 30, 2026
Bank of America1.29M0.66%US$3.7MSep 30, 2026
UBS951K0.49%US$2.72MSep 30, 2026
Barclays922K0.47%US$2.64MSep 30, 2026
Morgan Stanley850K0.44%US$2.43MSep 30, 2026
Ghisallo Capital Management LLC750K0.39%US$2.15MSep 30, 2026
Hennion & Walsh Asset Management, Inc.745K0.38%US$2.13MSep 30, 2026
Squarepoint Ops LLC741K0.38%US$2.12MSep 30, 2026
Citadel694K0.36%US$1.98MSep 30, 2026
BNY671K0.34%US$1.92MSep 30, 2026
Tang Capital Management LLC666K0.34%US$1.9MSep 30, 2026
Wellington664K0.34%US$1.9MSep 30, 2026
Dimensional627K0.32%US$1.79MSep 30, 2026
Schwab608K0.31%US$1.74MSep 30, 2026
D. E. Shaw & Co., Inc.574K0.29%US$1.64MSep 30, 2026
BNP Paribas460K0.24%US$1.32MSep 30, 2026
Beirne Wealth Consulting Services, LLC422K0.22%US$1.21MSep 30, 2026
Balyasny Asset Management L.P.403K0.21%US$1.15MSep 30, 2026
HSBC379K0.19%US$1.12MSep 30, 2026
Invesco344K0.18%US$983KSep 30, 2026
Hrt Financial LP339K0.17%US$970KSep 30, 2026
Elo Mutual Pension Insurance Co328K0.17%US$939KSep 30, 2026
Rhumbline Advisers320K0.16%US$916KSep 30, 2026
Janney Montgomery Scott LLC313K0.16%US$894KSep 30, 2026
LMR Partners LLP300K0.15%US$858KSep 30, 2026
Steward Partners Investment Advisory, LLC268K0.14%US$766KSep 30, 2026
Alps Advisors Inc256K0.13%US$732KSep 30, 2026
Brown Wealth Management, LLC240K0.12%US$687KSep 30, 2026
Baird Financial Group, Inc.238K0.12%US$679KSep 30, 2026
Stifel Financial Corp212K0.11%US$607KSep 30, 2026

This page holds 50 of 184 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF8.1M4.2%US$24.6MJun 30, 2026
Vanguard Total Stock Market Index Fund5.75M3.0%US$17.5MJun 30, 2026
iShares Russell 2000 ETF5.16M2.7%US$15.7MJun 30, 2026
Vanguard Strategic Equity Fund2.52M1.3%US$7.66MJun 30, 2026
Vanguard Extended Market Index Fund2.24M1.1%US$6.8MJun 30, 2026
Fidelity Small Cap Index Fund2.17M1.1%US$6.17MJul 31, 2026
iShares Russell 2000 Value ETF1.87M0.96%US$5.68MJun 30, 2026
iShares Biotechnology ETF1.3M0.67%US$3.94MJun 30, 2026
Vanguard Explorer Fund1.21M0.62%US$3.45MJul 31, 2026
BlackRock Advantage Small Cap Core Fund1.05M0.54%US$3.19MMay 29, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund988K0.51%US$3.01MMay 31, 2026
Vanguard Strategic Small-Cap Equity Fund867K0.45%US$2.64MJun 30, 2026
Vanguard Russell 2000 Index Fund670K0.34%US$2.04MMay 31, 2026
iShares Micro-Cap ETF668K0.34%US$2.03MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF638K0.33%US$1.94MJun 30, 2026
Vanguard Health Care Index Fund567K0.29%US$1.73MMay 31, 2026
Schwab Small-Cap Index Fund484K0.25%US$1.37MJul 31, 2026
Vanguard Market Neutral Fund401K0.21%US$1.22MJun 30, 2026
Master Small Cap Index Series372K0.19%US$1.13MJun 30, 2026
Fidelity Total Market Index Fund357K0.18%US$1.09MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF356K0.18%US$1.08MJun 30, 2026
Fidelity Series Total Market Index Fund290K0.15%US$886KMay 31, 2026
Fidelity Small Cap Value Index Fund278K0.14%US$845KJun 30, 2026
Small Company Growth Portfolio277K0.14%US$841KJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares275K0.14%US$781KJul 31, 2026
Nuveen Small Cap Blend Index Fund265K0.14%US$752KJul 31, 2026
BlackRock Advantage Small Cap Growth Fund233K0.12%US$709KJun 30, 2026
EQ/2000 Managed Volatility Portfolio216K0.11%US$657KJun 30, 2026
U.S. Micro Cap Portfolio211K0.11%US$598KJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF184K0.09%US$522KJul 31, 2026
Dimensional U.S. Small Cap ETF168K0.09%US$476KJul 31, 2026
LVIP State Street Small-Cap Index Fund143K0.07%US$434KJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account141K0.07%US$430KJun 30, 2026
Schwab Total Stock Market Index Fund141K0.07%US$400KJul 31, 2026
ALPS Medical Breakthroughs ETF134K0.07%US$409KMay 31, 2026
Vanguard Russell 2000 Growth Index Fund122K0.06%US$371KMay 31, 2026
Virtus Biotech Clinical Trials Etf119K0.06%US$338KJul 31, 2026
Fidelity ZERO Total Market Index Fund113K0.06%US$322KJul 31, 2026
Small Cap Index Fund103K0.05%US$313KJun 30, 2026
Nomura Healthcare Fund100K0.05%US$304KJun 30, 2026
Nuveen Equity Index Fund99,7270.05%US$283KJul 31, 2026
Vanguard Balanced Index Fund99,5510.05%US$303KJun 30, 2026
Global X Russell 2000 ETF94,9690.05%US$270KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund94,0010.05%US$286KJun 30, 2026
VIP Disciplined Small Cap Portfolio90,0740.05%US$274KJun 30, 2026
EQ/Small Company Index Portfolio80,2900.04%US$244KJun 30, 2026
Diversified Equity Alpha Master Portfolio77,5720.04%US$236KJun 30, 2026
Biotechnology Ultrasector Profund77,1990.04%US$219KJul 31, 2026
Fidelity Nasdaq Composite Index Fund74,6120.04%US$228KMay 31, 2026
Fidelity ZERO Extended Market Index Fund72,1160.04%US$205KJul 31, 2026

This page holds 50 of 133 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Menziuso Richard Thomas
Officer: Principal Accounting Officer
Buy10,000USD 1.42US$14,187Nov 18, 2026
Weaver Gregory L
Officer: Chief Financial Officer
Buy10,000USD 1.62US$16,200Nov 13, 2026
Durso Jerome Benedict
Director, Officer: President and CEO
Buy30,700USD 1.62US$49,694Nov 13, 2026
Pisano Wayne
Director
Buy10,000USD 1.64US$16,350Nov 13, 2026
Durso Jerome Benedict
Director, Officer: President and CEO
Buy15,000USD 2.95US$44,250Aug 13, 2026
Gill John
Director
Buy9,200USD 3.41US$31,372Apr 6, 2026
Weaver Gregory L
Officer: Chief Financial Officer
Buy10,000USD 3.15US$31,500Apr 1, 2026
Durso Jerome Benedict
Director, Officer: President and CEO
Buy15,000USD 3.14US$47,100Apr 1, 2026

Big stakes

StakeStakeSharesDateFiling
Deep Track Capital, LP9.99%19.4MApr 23, 2026Schedule 13G
BlackRock, Inc.7.60%6.13MJun 30, 2025Schedule 13G
Viking Global Investors LP6.70%13.4MApr 24, 2026Schedule 13G
Ra Capital Management, L.P.6.50%13MApr 24, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Derace L Schaffer
Other companies: Lantheus Holdings, Inc. (Director · Mar 4, 2016 – Mar 3, 2020 · Past); American Caresource Holdings Inc (Director · Jul 20, 2010 – Jun 14, 2012 · Past); King Pharmaceuticals Inc (Director · May 14, 2010 – Jan 31, 2011 · Past)
Director · May 17, 2010 – Dec 28, 2017 · Past
Richard I Eisenstadt
Other companies: Aytu BioPharma, Inc. (Chief Financial Officer · Mar 31, 2021 – Mar 31, 2021 · Past); Neos Therapeutics Inc (Chief Financial Officer · Mar 2, 2020 – Mar 19, 2021 · Past)
Chief Financial Officer · Dec 31, 2021 – Jan 30, 2024 · Past
Wayne Pisano
Other companies: Oncolytics Biotech Inc. (Director · Since at least Jun 26, 2025); Provention Bio Inc (Director · Jul 3, 2018 – Apr 27, 2023 · Past)
Director · Since at least Aug 30, 2018
Gregory L Weaver
Other companies: Atossa Therapeutics, Inc. (Former EVP, CFO, & Director, Director · May 17, 2019 – Nov 15, 2023 · Past)
Chief Financial Officer · Since at least Nov 11, 2024
John M. Gill
Other companies: Tetralogic Pharmaceuticals Corp (Director · Dec 11, 2013 – Dec 31, 2013 · Past)
Director · Since at least Jun 11, 2013
Alex HowarthDirector · Since at least Oct 27, 2026
Catherine Angell SohnDirector · Since at least Nov 5, 2026
Christophe Arbet-EngelsChief Medical Officer · Since at least Aug 3, 2026
David DrutzDirector · May 4, 2017 – Aug 19, 2024 · Past
Diane K. JorkaskyDirector · Since at least Nov 5, 2026
All 27 people
PersonSeat
Francesca M CookSVP, Policy & Gov't Affairs · Dec 1, 2011 – Dec 8, 2014 · Past
Greg WeaverChief Financial Officer · Since at least Sep 15, 2025
Jeffrey Michael JonesCOO · Mar 11, 2015 – Mar 11, 2015 · Past
Jerome DursoPresident, Chief Executive Officer and Chairman Of The Board · Since at least Aug 13, 2026
Joel McClearyDirector · Jun 23, 2010 – Dec 31, 2014 · Past
Klaus SchaferDirector · Since at least May 4, 2017
Linda M. RichardsonChief Commercial Officer · Since at least Nov 6, 2025
Matthew Scott HarrisChief Medical Officer · Since at least Sep 9, 2019
Mitchel SayareDirector · Since at least Oct 27, 2026
Peter GreenleafDirector · Since at least Oct 27, 2026
Philip HodgesDirector · Since at least Nov 4, 2026
Philip HodgesDirector · Since at least May 4, 2017
Richard Thomas MenziusoPrincipal Accounting Officer · Since at least Nov 18, 2026
Robin E. AbramsChief Legal Officer · Since at least Nov 6, 2025
Scot RobertsChief Scientific Officer · Since at least May 4, 2017
Teri LawverDirector · Since at least Feb 25, 2025
Thomas Richard FuerstEVP, Chief Scientific Officer · Apr 5, 2010 – Dec 1, 2011 · Past

Open People

Log in to ask 6ix AI your own questions about Altimmune, Inc.